Main PROMs used in clinical trials of hematologic and solid tumor
| PROM | Main focus | Reference in the ACT field (if any) |
| SF-36 | HRQOL (generic, health status) | Tam et al11 |
| EQ-5D-5L | HRQOL (generic, health status) | Elsawy et al 2021 Shah et al 2020 |
| FACT-G | HRQOL (cancer-specific) | Sidana et al12 |
| EORTC QLQ-C30 (±disease-specific modules) | HRQOL (cancer-specific) | Elsawy et al Shah et al Abramson et al13–15 |
| Visual Analog Scale for pain or other symptoms | Pain | |
| PROMIS | HRQOL (global health, cognitive function, pain, sleep disturbance) | Mullane et al16 |
| Hospital Anxiety and Depression Scale | Anxiety and depression | Ursu et al17 |
| Inventory of depression and anxiety symptoms | Anxiety and depression | Ruark et al7 |
| COST-FACIT | Financial toxicity | Cusatis et al18 |
ACT, adoptive cell therapies; COST-FACIT, COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30; EQ-5D-5L, EuroQoL-5 dimension-5 level; FACT-G, Functional Assessment of Cancer Therapy-General; HRQoL, health-related quality of life; PROM, patient-reported outcome measures; PROMIS, Patient-Reported Outcomes Measurement Information System; SF-36, 36-Item Short Form Health Survey.